Throughout this period, CNV in the right eye remained inactive and the final visual acuity in the right eye was 20/20.[101] Since TIMP-3 can regulate the secretion of TNF-α locally, the author suggests that the use of anti-TNF-α agents such as adalimumab may offer a molecularly oriented approach to treatment and warrants further evaluation.[101] Therefore, larger prospective studies are required to elucidate whether adalimumab could be a good alternative treatment for CNV secondary to SFD. The gene discussed is TIMP3; the disease is Sorsby fundus dystrophy.